Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press11510.17650/2313-805X-2017-4-4-24-31RESEARCH ARTICLESЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИANALYSIS OF RELATIVE EXPRESSION OF THE HMGA2 GENE AND ONCOGENIC MICRORNA-221 IN CYTOLOGICAL SLIDES OBTAINED BY A FINE-NEEDLE ASPIRATION BIOPSY OF THE THYROID NODULESАНАЛИЗ ОТНОСИТЕЛЬНОЙ ЭКСПРЕССИИ ГЕНА HMGA2 И ОНКОГЕННОЙ МИКРОРНК-221 В ЦИТОЛОГИЧЕСКИХ ПРЕПАРАТАХ, ПОЛУЧЕННЫХ ПРИ ТОНКОИГОЛЬНОЙ АСПИРАЦИОННОЙ БИОПСИИ УЗЛОВ ЩИТОВИДНОЙ ЖЕЛЕЗЫTitovS. E.ТитовС. Е.
Russian Federation

8/2 Acad. Lavrent’eva prospect, Novosibirsk 630090

Сергей Евгеньевич Титов.

630090 Новосибирск, проспект акад. Лаврентьева, 8/2

titovse78@gmail.comIvanovM. K.ИвановМ. К.
Russian Federation

8/2 Acad. Lavrent’eva prospect, Novosibirsk 630090

630090 Новосибирск, проспект акад. Лаврентьева, 8/2

TsivlikovaE. V.ЦивликоваЕ. В.
Russian Federation

36 Scientific-production zone, Kol’tsovo, Novosibirsk Oblast 630559

630559 Новосибирская область, пос. Кольцово, Научно-производственная зона, корпус 36

GanzhaM. S.ГанжаМ. С.
Russian Federation

36 Scientific-production zone, Kol’tsovo, Novosibirsk Oblast 630559

630559 Новосибирская область, пос. Кольцово, Научно-производственная зона, корпус 36

MalakhinaE. S.МалахинаЕ. С.
Russian Federation

8/2 Acad. Lavrent’eva prospect, Novosibirsk 630090

630090 Новосибирск, проспект акад. Лаврентьева, 8/2

MalekA. V.МалекА. В.
Russian Federation

68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758; 5 Railway Clinical Hospital on the Station Novosibirsk-Glavniy

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 194356 Санкт-Петербург, ул. Хошимина, 11;

PolozT. L.ПолозТ. Л.
Russian Federation

2a Vladimirovskiy Spusk, Novosibirsk 630003

630003 Новосибирск, Владимировский спуск, 2а

ShevchenkoS. P.ШевченкоС. П.
Russian Federation

6 Zalesskogo St., Novosibirsk 630047

630047 Новосибирск, ул. Залесского, 6

KolesnikovN. N.КолесниковН. Н.
Russian Federation

8/2 Acad. Lavrent’eva prospect, Novosibirsk 630090

630090 Новосибирск, проспект акад. Лаврентьева, 8/2

Institute of Molecular and Cell Biology Siberian branch of Russian Academy of SciencesИнститут молекулярной и клеточной биологии СО РАНVector-BestbuildАО «Вектор-Бест»АО «Вектор-Бест»Institute of Molecular and Cell Biology Siberian branch of Russian Academy of SciencesИнститут молекулярной и клеточной биологии СО РАНN.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaOncosystemФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России11 Khoshimina St., Saint Petersburg 194356ООО «Онко-система»Railway Clinical Hospital on the Station Novosibirsk-GlavniyНУЗ «Дорожная клиническая больница на ст. Новосибирск-Главный ОАО «РЖД»City Clinical Hospital No. 1ГБУЗ НО «Городская клиническая больница № 1»Institute of Molecular and Cell Biology Siberian branch of Russian Academy of SciencesИнститут молекулярной и клеточной биологии СО РАН151220174424310212201702122017Copyright ©; 2017, Titov S.E., Ivanov M.K., Tsivlikova E.V., Ganzha M.S., Malakhina E.S., Malek A.V., Poloz T.L., Shevchenko S.P., Kolesnikov N.N.Copyright ©; 2017, Титов С.Е., Иванов М.К., Цивликова Е.В., Ганжа М.С., Малахина Е.С., Малек А.В., Полоз Т.Л., Шевченко С.П., Колесников Н.Н.2017Titov S.E., Ivanov M.K., Tsivlikova E.V., Ganzha M.S., Malakhina E.S., Malek A.V., Poloz T.L., Shevchenko S.P., Kolesnikov N.N.Титов С.Е., Иванов М.К., Цивликова Е.В., Ганжа М.С., Малахина Е.С., Малек А.В., Полоз Т.Л., Шевченко С.П., Колесников Н.Н.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/115

thyroid cancermolecular markersHMGA2microRNA-221fine needle aspiration biopsyрак щитовидной железымолекулярные маркерыHMGA2микроРНК-221тонкоигольная аспирационная пункционная биопсияThe study was conducted with financial support for basic scientific research under the projects 0310-2014-0002; 0310-2015-0003; 0310-2015-0007Фундаментальные научные исследования по темам 0310-2014-0002; 0310-2015-0003; 0310-2015-00071. Ghossein R. Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch Pathol Lab Med 2009;133(5):683–91.Ghossein R. Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch Pathol Lab Med 2009;133(5):683–91.2. Baloch Z.W., Sack M.J., Yu G.H. et al. Fine-needle aspiration of thyroid: an institutional experience. Thyroid 1998;8(7):565–9.Baloch Z.W., Sack M.J., Yu G.H. et al. Fine-needle aspiration of thyroid: an institutional experience. Thyroid 1998;8(7):565–9.3. Pallante P., Sepe R., Puca F., Fusco A. High mobility group a proteins as tumor markers. Front Med (Lausanne) 2015;2:15.Pallante P., Sepe R., Puca F., Fusco A. High mobility group a proteins as tumor markers. Front Med (Lausanne) 2015;2:15.4. Cleynen I., Van de Ven W.J. The HMGA proteins: a myriad of functions (Review). Int J Oncol 2008;32(2):289–305.Cleynen I., Van de Ven W.J. The HMGA proteins: a myriad of functions (Review). Int J Oncol 2008;32(2):289–305.5. Wang X., Liu X., Li A.Y. et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res 2011;17(8):2570–80.Wang X., Liu X., Li A.Y. et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res 2011;17(8):2570–80.6. Ding X., Wang Y., Ma X. et al. Expression of HMGA2 in bladder cancer and its association with epithelial-tomesenchymal transition. Cell Prolif 2014;47(2):146–51.Ding X., Wang Y., Ma X. et al. Expression of HMGA2 in bladder cancer and its association with epithelial-tomesenchymal transition. Cell Prolif 2014;47(2):146–51.7. Chiappetta G., Tallini G., De Biasio M.C. et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58(18):4193–8.Chiappetta G., Tallini G., De Biasio M.C. et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58(18):4193–8.8. Raskin L., Fullen D.R., Giordano T.J. et al. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol 2013;133(11):2585–92.Raskin L., Fullen D.R., Giordano T.J. et al. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol 2013;133(11):2585–92.9. Malek A., Bakhidze E., Noske A. et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008;123(2):348–56.Malek A., Bakhidze E., Noske A. et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008;123(2):348–56.10. Belge G., Meyer A., Klemke M. et al. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 2008;47(1):56–63.Belge G., Meyer A., Klemke M. et al. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 2008;47(1):56–63.11. Lappinga P.J., Kip N.S., Jin L. et al. HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol 2010;118(5):287–97.Lappinga P.J., Kip N.S., Jin L. et al. HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol 2010;118(5):287–97.12. Jin L., Lloyd R.V., Nassar A. et al. HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RTPCR. Diagn Mol Pathol 2011;20(2):71–80.Jin L., Lloyd R.V., Nassar A. et al. HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RTPCR. Diagn Mol Pathol 2011;20(2):71–80.13. Nagar S., Ahmed S., Peeples C. et al. Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid neoplasms. Am J Surg 2014;207(4):596–601.Nagar S., Ahmed S., Peeples C. et al. Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid neoplasms. Am J Surg 2014;207(4):596–601.14. Берёзкина И.С., Саприна Т.В., Зима А.П. и др. Исследование галектина-3, Ki-67, убиквитина, HMGA2 методом полимеразной цепной реакции в режиме реального времени в пункционном материале при узловом зобе. Клиническая и экспериментальная тиреоидология 2016;12(2):19–27. [Berezkina I.S., Saprina T.V., Zima A.P. et al. The study of galectin-3, Ki-67, ubiquitin, HMGA-2 by polymerase chain reaction in real time (RT-PCR) in the puncture specimens of nodular goiter. Klinicheskaya i eksperimental’naya tireoidologiya = Clinical and Experimental Thyroidology 2016;12(2):19–27. (In Russ.)].Берёзкина И.С., Саприна Т.В., Зима А.П. и др. Исследование галектина-3, Ki-67, убиквитина, HMGA2 методом полимеразной цепной реакции в режиме реального времени в пункционном материале при узловом зобе. Клиническая и экспериментальная тиреоидология 2016;12(2):19–27. [Berezkina I.S., Saprina T.V., Zima A.P. et al. The study of galectin-3, Ki-67, ubiquitin, HMGA-2 by polymerase chain reaction in real time (RT-PCR) in the puncture specimens of nodular goiter. Klinicheskaya i eksperimental’naya tireoidologiya = Clinical and Experimental Thyroidology 2016;12(2):19–27. (In Russ.)].15. Garofalo M., Quintavalle C., Romano G. et al. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012;12(1):27–33.Garofalo M., Quintavalle C., Romano G. et al. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012;12(1):27–33.16. Urbich C., Kuehbacher A., Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular Res 2008;79(4):581–8.Urbich C., Kuehbacher A., Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular Res 2008;79(4):581–8.17. Galardi S., Mercatelli N., Giorda E. et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem 2007;282(32):23716–24.Galardi S., Mercatelli N., Giorda E. et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem 2007;282(32):23716–24.18. He H., Jazdzewski K., Li W. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102(52):19075–80.He H., Jazdzewski K., Li W. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102(52):19075–80.19. Nikiforova M.N., Tseng G.C., Steward D. et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93(5):1600–8.Nikiforova M.N., Tseng G.C., Steward D. et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93(5):1600–8.20. Dettmer M., Vogetseder A., Durso M.B. et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab 2013;98(1):E1–7.Dettmer M., Vogetseder A., Durso M.B. et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab 2013;98(1):E1–7.21. Wojtas B., Ferraz C., Stokowy T. et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol 2014;388(1–2):1–9.Wojtas B., Ferraz C., Stokowy T. et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol 2014;388(1–2):1–9.22. Cibas E.S., Ali S.Z. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009;132(5):658–65.Cibas E.S., Ali S.Z. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009;132(5):658–65.23. Titov S.E., Ivanov M.K., Karpinskaya E.V. et al. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. BMC Cancer 2016;16:201.Titov S.E., Ivanov M.K., Karpinskaya E.V. et al. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. BMC Cancer 2016;16:201.24. Titov S.E., Demenkov P.S., Ivanov M.K. et al. Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. Oncol Rep 2016;36(5):2501–10.Titov S.E., Demenkov P.S., Ivanov M.K. et al. Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. Oncol Rep 2016;36(5):2501–10.25. Chiappetta G., Ferraro A., Vuttariello E. et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 2008;44(7):1015–21.Chiappetta G., Ferraro A., Vuttariello E. et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 2008;44(7):1015–21.26. Jang M.H., Jung K.C., Min H.S. The diagnostic usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in follicular thyroid carcinoma. J Pathol Transl Med 2015;49(2):112–7.Jang M.H., Jung K.C., Min H.S. The diagnostic usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in follicular thyroid carcinoma. J Pathol Transl Med 2015;49(2):112–7.